|
| 胰岛素样生长因子结合球蛋白(IGFBP)与骨质疏松症相互关系的探究 |
| The relationship between insulin-like growth factor binding globulin (IGFBP) and osteoporosis |
| |
| DOI：10.3969/j.issn.1006-7108.2016.10.023 |
| 中文关键词: 胰岛素样生长因子结合球蛋白 骨质疏松症 成骨细胞 |
| 英文关键词:Insulin-like growth factor binding globulin Osteoporosis Osteoblast |
| 基金项目: |
|
| 摘要点击次数: 1281 |
| 全文下载次数: 586 |
| 中文摘要: |
| 骨质疏松症的高发病率及其继发的脆性骨折给老年骨质疏松患者健康造成了巨大威胁，近年来，得益于骨质疏松的生理病理学机制探究，临床上涌现出多种的治疗方案，并取得了一定的治疗效果，然而，当前治疗骨质疏松的药物主要以两种途径，一是抑制破骨细胞的骨吸收，可以达到短期内防止骨量快速丢失，缺点是长期应用会使骨折老化，陈旧，脆性增加，增大了脆性骨折的发生率；另一类是以促进骨形成为主，如PTH片段，但是长期应用副作用大，甚至会诱发肿瘤。因而寻找新的骨质疏松药物靶点，设计新的药物，成为迫切需要解决的问题。随着蛋白质组学技术的发展，越来越多的骨质疏松作用相关蛋白被发现，为新药的研制提供了新的契机，而胰岛素样生长因子结合球蛋白(IGFBP) 是目前被认为与骨质疏松症高度相关的一个靶蛋白，但机制及当前情况却鲜被提及，本文就胰岛素样生长因子结合球蛋白(IGFBP)与骨质疏松的相关研究进展进行综述。 |
| 英文摘要: |
| High prevalence of osteoporosis and the consequent fragility fracture have become a huge threat to elderly osteoporotic patients. With the pathophysiological mechanisms of osteoporosis are better understood, many clinical treatments have emerged and achieved certain therapeutic effects in recent years. There are mainly two types of medications for osteoporosis. One inhibits bone absorption by osteoclasts, which can prevent bone loss rapidly in a short time. But it would increase the fragility of bone in a long term application, and consequently increase the risk of fragility fractures. Another type of medication can promote bone formation (e.g. PTH fragment), but long-term usage of it can cause serious side effects, such as tumor. To find a new drug target for osteoporosis has become an urgent task. With the development of proteomics, more and more osteoporosis-related proteins have been found, which provides opportunities for the development of new drugs. Insulin-like growth factor binding globulin (IGFBP) is regarded as a highly osteoporosis-related protein, but the mechanism of its effect is still rarely mentioned. This review summarizes the research progress on the relationship between IGFBP and osteoporosis. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |